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Fourier transform infrared (FTIR) spectroscopy is a vibrational spectroscopic technique that uses infrared radiation to vibrate
molecular bonds within the sample that absorbs it. As different samples contain different molecular bonds or different configurations
of molecular bonds, FTIR allows us to obtain chemical information on molecules within the sample. Fourier transform infrared
microspectroscopy in conjunction with a principal component-discriminant function analysis (PC-DFA) algorithm was applied to the
grading of prostate cancer (CaP) tissue specimens. The PC-DFA algorithm is used alongside the established diagnostic measures of
Gleason grading and the tumour/node/metastasis system. Principal component-discriminant function analysis improved the sensitivity
and specificity of a three-band Gleason score criterion diagnosis previously reported by attaining an overall sensitivity of 92.3% and
specificity of 99.4%. For the first time, we present the use of a two-band criterion showing an association of FTIR-based spectral
characteristics with clinically aggressive behaviour in CaP manifest as local and/or distal spread. This paper shows the potential for the
use of spectroscopic analysis for the evaluation of the biopotential of CaP in an accurate and reproducible manner.
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Prostate cancer (CaP) is the most common cancer and second
most common cause of cancer-related deaths of men in the United
Kingdom, with 10 164 deaths in 2003 (Cancer Research UK, 2006).
The diagnosis of CaP and in particular, the prediction of
biopotential in individual patients can be very problematic.
Biopotential refers to the ability of the disease to progress to
severe cancer. This has led to an inappropriate treatment and
pathological upstaging in some cases and an overtreatment of
biologically indolent disease in others (Parker et al, 2006).
Confirmation of initial diagnosis involves a biopsy and use of
the Gleason grading system for histological analysis. This
technique, which is the mainstay for diagnosis and prediction of
tumour biopotential, utilises the Gleason grading system (Gleason,
1977) based on tumour morphology, identifying a complex
continuum of glandular architecture enabling the grouping of
cancer types into five visually distinct grades. This technique,
although widely used, has well-recognised flaws. In particular,
there are many theoretically low-grade/‘low-biopotential’ tumours,
which show evidence of progression and in addition, there is
considerable inter- and intra-observer error in the assignation of
the final tumour grade. In a study of 390 patients, identical grades
were assigned to only 29.2% of tumours (Latouf and Saad, 2002),
and a UK-based study using 81 CaP slides found that on first
readings the consensus score was only 78% (Melia et al, 2006).
The limitation with these diagnostic modalities has led to an
interest in the development of spectroscopic analytical techniques
for the diagnosis of cancer. Infrared (IR) spectroscopy is a non-
destructive method for the analysis of tissues, fluids and cells
(Sahu and Mordechai, 2005). Infrared radiation causes vibration
of the bonds of the molecules within the sample that absorbs
it. The wavelength of the IR radiation absorbed depends on
the atoms involved in the bond and the strength of any
intermolecular interactions. Therefore, each molecule can have a
different spectrum; in essence, the IR spectrum is a fingerprint of
the sample. Infrared spectra of biomolecules allow the measure-
ment of complex molecular vibrational modes that contain
valuable information on changes occurring due to diseases such
as cancer. Infrared spectroscopy is a quick, cost-effective, simple-
to-operate, reagent-free technique that requires simple sample
preparation.
Fourier transform infrared (FTIR) spectroscopy coupled with
advanced computational methods has been used to detect many
different forms of cancer from tissue biopsies. These include
benign and malignant prostate (Gazi et al, 2003, 2004, 2006), colon
(Lasch et al, 2002) and cervical (Wood et al, 2004) tissues, all of
which have been evaluated using this technique and with a high
rate of diagnostic accuracy. In relation to grading of CaP, the
sensitivities and specificities reported earlier have been as high as
78 and 89%, respectively, using a Fourier transform infrared-linear
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discriminant analysis model to predict Gleason scores less than
7 (GSo7), equal to 7 (GS¼ 7) and greater than 7 (GS47) (Gazi
et al, 2006).
This paper discusses the use of FTIR microspectroscopy
combined with principal component-discriminant function analy-
sis (PC-DFA) to evaluate formalin-fixed archival CaP tissue based
upon a three-band and a two-band Gleason score criteria. The aim
of this paper is to determine the possible biochemical changes
associated with the progression of CaP and to observe whether
there are characteristic spectroscopic changes between prostate
confined and locally invasive tumours.
MATERIALS AND METHODS
Primary tissue preparation and sampling for FTIR
With full ethical committee approval, Trent MREC 01/4/061,
tissue was collected from 39 consenting patients undergoing
transurethral resection of the prostate for bladder outflow
obstruction. Forty CaP tissue biopsy specimens from 39 men
were obtained as paraffin-embedded blocks (Genito-Urinary
Cancer Research Group, Paterson Institute for Cancer Research)
from patients with CaP. The tissue was fixed in 4% formalin
for 24 h, then placed onto a Thermoshandon Excelsior processor
that passes 20, 90 and four 100% ethanol aliquots through the
tissue for an hour each, followed by three changes of xylene for an
hour each at a temperature of 401C, followed by three changes of
paraplast for an hour each at 621C. Then the tissue was embedded
in a mould of molten wax and cooled on an ice plate for an hour
before storage.
Serial sections were collected at 10 mm thickness from each
specimen, one of which was mounted onto a BaF2 plate (Linkham
Scientific Ltd, Tadworth, UK) with the adjacent section mounted
onto a glass slide and stained with haematoxylin and eosin (H&E).
An experienced histopathologist with a subspecialist interest in
genitourinary pathology, including participation in the UK
national prostate histopathology external quality assurance
scheme, assigned Gleason scores to areas of malignancy identified
within the H&E sections. The complementary sections of the same
cancer region were mounted onto BaF2 plates and washed on
an orbital mixer with citroclear for 6min to remove the paraffin
and then acetone at 41C for a further 6min before being air-dried
for 1 h under ambient conditions. The anatomical features
identified from the H&E section were used as landmarks to
position the IR beam upon the malignant lesions of the unstained
adjacent section.
FTIR microspectroscopy
Fourier transform infrared spectra of Gleason-graded primary
prostate tissues were collected in transmission mode using a
Nicole Magna system 550 spectrometre equipped with a liquid
nitrogen-cooled MCT/A detector and a KBr beam splitter. The
spectrometer is attached to a microscope equipped with a video
camera to view optical images ( 150 magnification) of the
sampling area and a programmable computerised x–y stage. An
aperture size of 60 60 mm was used to collect malignant epithelial
cell spectra. Fourier transform infrared spectra represent an
average of 512 scans in the mid-IR wavenumber range 750–
4000 cm1 with a spectral resolution of 4 cm1. Background scans
were obtained from a region outside the sample field and ratioed
against the sample spectrum. In total, 395 FTIR spectra were
obtained from the 40 CaP tissue biopsies from 39 patients with at
least five spectra recorded from each patient. The total number of
spectra acquired from each patient was dependent on the size of
the tumour lesion within the tissue section as well as on the
positive identification of tumour glands in the unstained tissue
section.
Data processing
Data processing was carried out immediately after spectral
acquisition using OMNIC v.5.1a software. OMNIC software was
used to convert the FTIR absorbance spectra into first derivatives
(Savitzky–Golay algorithm, nine smoothing points) and second
derivatives. The spectral region used was 750.1859–3999.706 cm1
with the variable CO2 region from 1847.501 to 2809.22 cm
1
removed. This resulted in 1188 spectral data points for analysis.
The spectra were then vector normalised in Matlabt, to correct for
baseline shifts (scattering). Three different pre-processing proce-
dures were used on raw spectra and assessed for optimum
discrimination; these steps were (1) vector normalisation (model
A), (2) vector normalisation combined with first derivatisation
(model B) and (3) vector normalisation combined with second
derivatisation (model C). Figure 1 shows raw spectral data and the
effect of three pre-processing steps above on an example subset of
the FTIR data with the variable CO2 region removed. Matlab
coupled with an in-house written software was used to perform
PC-DFA. Principal component-discriminant function analysis uses
principal component analysis to reduce the dimensionality of the
data before DFA. Discriminant function analysis then discrimi-
nates between groups on the basis of the resulting PCs and the a
priori knowledge of the group memberships that are fed into the
DFA algorithm (Baker et al, 2008). Maximising the inter-group
variance and minimising the intra-group variance achieve this.
The maximum number of discriminant functions available is the
number of groups minus one. The optimum number of PCs was
determined through an iterative process of chemometric model
generation and validation. Discriminant function analysis is a
supervised technique and the model is supplied with information
about group membership, so any result produced by the model
needs to be tested. This testing was carried out by retaining one-
fifth of the total filtered pre-processed spectra, randomly selected
as an independent test set, and then supplying the spectra to the
model as a test set and observing where the model places the
spectra on a graphical output. Error ellipses with 95 and 90%
confidence are added to the discriminant function plots. This was
achieved using error_ellipse.m written by AJ Johnson and obtained
from Matlab central file exchange. Covariance matrices were
calculated from the discriminant function analysis score matrix for
each grouping, where the centroid was defined as the mean of the
discriminant function analysis score matrix for each grouping.
RESULTS
Correlation of FTIR PC-DFA spectral signature with
Gleason score
The FTIR PC-DFA diagnostic model was derived from 40 CaP
tissue biopsies. The 40 biopsies correspond to 395 spectra (90
spectra from 10 biopsies for GSo7, 118 spectra from 11 biopsies
for GS¼ 7 and 187 spectra from 19 biopsies for GS47). Spectra
were divided into a training set consisting of 315 spectra (72
spectra from GSo7, 94 spectra from GS¼ 7 and 149 spectra from
GS47) and a randomly chosen test set consisting of a fifth of the
total data set of 80 spectra (18 spectra from GSo7, 24 spectra from
GS¼ 7 and 38 spectra from GS47). The CaP diagnostic model
was built on the training set data and it was at this stage
that spectroscopic similarities and differences between spectra
collected from different Gleason scores were determined by the
PC-DFA algorithm, in a supervised manner. The test set was then
used to interrogate the model classification of the different spectra.
The Gleason score is the sum of the predominant and highest
Gleason grades observed within a biopsy. When the biopsy has
only one Gleason grade, this grade is doubled to produce the
resulting Gleason score (Gleason, 1977). A three-band Gleason
score criterion was used that divided specimens into groups
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corresponding to GSo7, GS¼ 7 and GS47. This method is a more
clinically orientated scale in which Gleason scores o7 are less
aggressive, Gleason¼ 7 are of intermediate biopotential and
Gleason scores 47 are the most likely to progress. This grouping
has been shown earlier to be characterised by specific FTIR
spectral characteristics (Gazi et al, 2006). Table 1 shows the
sensitivity and specificity observed for each of the bands in the
criterion at 95% and stringent 90% confidence limits for models
obtained using three different data analysis pre-processing steps.
These models are (A) spectra vector normalised, (B) spectra vector
normalised followed by first derivative and (C) spectra vector
normalised followed by second derivative. Sensitivity refers to the
proportion of people with disease who have a positive test result
and specificity refers to the proportion of people without the
disease who have a negative test result.
Model B (vector normalised combined with first derivative)
achieves the greatest overall sensitivity of 92.3% for the models at
the 95% confidence limit. The overall sensitivity is the average of
the three measurements attained when discriminating the three
groups (GSo7, GS¼ 7 and GS47). Figure 2 shows the discrimi-
nant function plot for model B showing separation based upon the
training set (red digits) and test set (blue digits) with 95% (blue
ellipse) and 90% (green ellipse) confidence limits, where
1¼GSo7, 2¼GS¼ 7 and 3¼GS47.
Table 1 Sensitivities and specificities observed for less than 7, equal to 7
and greater than 7 Gleason score at 95 and 90% confidence limits and
overall sensitivities and specificities for (i) model A (vector normalised), (ii)
model B (vector normalised with first derivative) and (iii) model C (vector
normalised with second derivative)
Gleason score GSo7 GS¼ 7 GS47 Overall
(i)
Confidence limit 95% 90% 95% 90% 95% 90% 95% 90%
Sensitivity (%) 94.4 88.8 83.3 70.8 86.8 76.3 88.2 78.6
Specificity (%) 100 100 98.2 98.2 100 100 99.4 99.4
(ii)
Confidence limit 95% 90% 95% 90% 95% 90% 95% 90%
Sensitivity (%) 88.9 83.3 95.8 91.7 92.1 89.5 92.3 88.2
Specificity (%) 98.4 100 98.2 98.2 100 100 98.9 99.4
(iii)
Confidence limit 95% 90% 95% 90% 95% 90% 95% 90%
Sensitivity (%) 61.1 61.1 91.7 87.5 81.6 76.2 78.1 74.9
Specificity (%) 98.4 100 94.6 96.4 97.6 97.6 96.9 98
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Figure 2 Discriminant function plot showing separation of model B (first
derivative vector normalised) based upon the training set (red digits) and
test set (blue digits) with 95% (blue ellipse) and 90% (green ellipse)
confidence limits, where 1¼Gleason score less than 7, 2¼Gleason score
equal to 7 and 3¼Gleason score greater than 7. DFA – DF1 vs DF2.
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Figure 1 Raw spectral data (A) and the effect of three pre-processing steps above on an example subset of the FTIR data with the variable CO2 region
removed. (B) Vector normalisation (model A), (C) vector normalisation combined with first derivatisation (model B) and (D) vector normalisation
combined with second derivatisation (model C).
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Discerning the peaks responsible for discrimination from
factor loadings based upon a first derivative spectral model is
particularly difficult as the peak in the raw spectrum becomes
a point on the baseline in the first derivative. The use of the
first derivative in pre-processing spectra removes the additive
baseline shift and enhances the chemical information available for
discrimination. However, as model A achieves the highest overall
specificity of 99.4% at the 95% confidence limit from spectra that
have only been vector normalised (to remove baseline shifts),
model A can be used to indicate which peaks are responsible for
discrimination. Figure 3A shows the discriminant function plot for
model B based upon training and test set data with confidence
ellipses as in Figure 2.Figure 3B and C shows the loading plots for
discriminant functions 1 and 2 from which we obtain the spectral
peaks responsible for discrimination in model A.
The axes of the discriminant function plot have positive and
negative directions (Figure 3). The peaks in the positive direction
of the y axis of the DF1 loading plots correspond to the spectral
peaks that the model is using to discriminate GSo7 and GS47
from GS¼ 7, and the peaks in the negative direction are used to
discriminate GS¼ 7 from GSo7 and GS47. The peaks in the
positive direction of discriminant function 2 correspond to the
spectral peaks used to discriminate GSo7 from GS47, and peaks
in the negative direction are used to discriminate GS47 from
GSo7. Table 2A shows the major spectral peaks responsible for
the Gleason score discrimination and proposed biomolecular
assignments for discriminant function 1 and Table 2B for
discriminant function 2.
Correlation of FTIR PC-DFA spectral signature with
clinical stage
The clinical stage is taken from the tumour/node/metastases
classification system. For the purpose of this experiment, we are
concerned with information from the primary tumour, investigat-
ing T1 and T2 tumours (confined to the prostate), T3 tumours
(breaching the prostate capsule or invading the seminal vesicle)
and T4 tumours (extending beyond the prostate and seminal
vesicle to invade local pelvic structures). N stages are classified as
N0, Nx (nodal status unknown) or Nþ (nodal status positive) and
M stage as M0 or M1. Definitive lymph node staging was not
available in T1 and T2 patients: these were designated N0. For the
same reasons, most low-stage and -grade tumours were designated
Mx.
Clinical staging information was available for 33 out of 39
patients. This corresponds to 347 spectra (191 spectra from 18
biopsies for T1 and T2 and 156 spectra from 15 biopsies for T3 and
T4). The spectra were split into a training set consisting of 276 (152
spectra from T1 and T2 and 124 spectra from T3 and T4) spectra
and a randomly chosen test set consisting of a fifth of the total data
set of 71 spectra (39 spectra from T1 and T2 and 32 spectra from
T3 and T4). No weighting criteria were applied to the spectra, so
each spectrum is of equal importance. Different number of spectra
from different groups in the model does not bias the model as we
are discriminating upon differences between groups and grouping
on similarities within groups.
In our study, a two-band criterion was used that divided
specimens into either stage T1 and T2 (confined to the prostate) or
T3 and T4 (extension outside the prostate). The sensitivity and
specificity calculations were based upon spectral assignment to
these criteria. If the spectrum was predicted to lie within the
correct group then this was counted as a positive prediction.
Table 3 shows the sensitivity and specificity observed for each of
the bands in the criterion at 95% and more stringent 90%
confidence limits for (A) model A – spectra vector normalised, (B)
model B – spectra vector normalised followed by first derivative
and (C) model C – spectra vector normalised followed by second
derivative.
The best-performing model is model A, which attained overall
sensitivity and specificity of 91.2 and 93.0%. This model used 62
0.015
0.01
0.005
–0.01
–0.02
0.2
0.15
0.1
0.05
0
–0.05
–0.1
–0.15
–0.2
0.2
0.15
0.1
0.05
0
–0.05
–0.1
–0.15
–0.2
–0.01
1541
12611653
2955 2848
1616
1460
2920
1664 1532
1603
1653
2850
2955
PC
-D
F2
 lo
ad
in
g
PC
-D
F2
 lo
ad
in
g
2910
0 0.01 0.02
Discriminant function 1
–0.005
0
4000 3500 3000 2500 2000
Wavenumber (cm–1) Wavenumber (cm–1)
1500 1000 500 4000 3500 3000 2500 2000 1500 1000 500
A
B C
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PCs and one discriminant function. Figure 4A shows the
discriminant function plot based upon the training set (red digits)
and test set (blue digits) with 95% (blue ellipse) and 90% (green
ellipse) confidence limits, where 1¼T1 and T2, and 2¼T3 and T4.
Figure 4B shows the loading plots for discriminant function 1,
from which it is possible to obtain the peaks responsible for
discrimination. As the model has only two groups, only one
discriminant function is sufficient for the separation.
The peaks in the positive direction of discriminant function 1
are used to discriminate T3 and T4 from T1 and T2, and the peaks
in the negative direction are used to discriminate T1 and T2 from
T3 and T4. Table 4 shows the major spectral peaks and possible
biomolecular assignments from discriminant function 1 that are
used to discriminate the two-band criteria.
DISCUSSION
Correlation of FTIR PC-DFA spectral signature with
Gleason score
Gleason grading of CaP biopsies is subject to both intra- and inter-
observer variability, which reduces any prognostic value arising
from the grading system (Latouf and Saad, 2002). Fourier
transform infrared vibrational spectroscopy determines the
chemical profile of a specimen by measuring the entire chemical
spectrum by means of absorbance of specific wavenumbers of IR
light, which relate to specific chemical bonds. These specific
absorbencies are due to bond vibrations, which correlate with
individual chemical groups. Interrogation and cross correlation of
these enable the acquisition of information detailing the chemical
Table 2 Major spectral peaks responsible for the Gleason score discrimination and proposed biomolecular assignments for (A) discriminant function 1
and (B) for discriminant function 2
Direction
Wavenumber
(cm1) Proposed biomolecular assignment
(A)
+ve 1063 C-O stretch, deoxyribose/ribose, DNA, RNA
+ve 1261 Amide III (NH bend (55%), C-C stretch (19%), C-N stretch (15%), CO bend (11%))
+ve 1265 Amide III ((NH bend (55%), C-C stretch (19%), C-N stretch (15%), CO bend (11%)) or PO2
 stretch, RNA, DNA
+ve 1541 Amide II of a-helical structures (NH bend (43%), C-N stretch (29%), CO bend (15%), C-C stretch (9%), N-C stretch (8%))
+ve 1653 Amide I of a-helical structures or unordered (C-O stretch (76%), C-N stretch (14%), CCN deformation (10%))
+ve 2910 C-H stretch (asymmetric) of 4CH2 in fatty acids, lipids, proteins
+ve 2920 C-H stretch (asymmetric) of 4CH2 in fatty acids, lipids, proteins
+ve 2966 C-H stretch (asymmetric) of CH3 in fatty acids, lipids, proteins
ve 1086 C-O, C-C stretches, C-O-H, C-O-C deformation of carbohydrates or PO2
 symmetric stretch of phosphodiester group in nucleic acids
and phospholipids
ve 1151 C-O, C-C stretch, C-O-H, C-O-C deformation of carbohydrates or C-OH stretch of serine, threonine, tyrosine in cell proteins
ve 1460 CH3 antisymmetric bend
ve 1473 CH2 scissoring
ve 1616 Amide I of aggregated strand protein structures (C-O stretch (76%), C-N stretch (14%), CCN deformation (10%))
ve 1650 Amide I of a-helical protein structures (C-O stretch (76%), C-N stretch (14%), CCN deformation (10%))
ve 1686 Amide I of antiparallel b-sheet/aggregated strand protein structures (C-O stretch (76%), C-N stretch (14%), CCN deformation (10%))
ve 2848 C-H symmetric stretch of 4CH2 in fatty acids, lipids and proteins
ve 2895 C-H stretch of C-H in methine groups
ve 2955 C-H asymmetric stretch of -CH3 in fatty acids, lipids and proteins
(B)
+ve 1065 C-O stretch, deoxyribose/ribose, DNA, RNA
+ve 1558 Amide II (NH bend (43%), C-N stretch (29%), CO bend (15%), C-C stretch (9%), N-C stretch (8%))
+ve 1653 Amide I of a-helical or unordered structures (C-O stretch (76%), C-N stretch (14%), CCN deformation (10%))
+ve 1683 Amide I of turns or antiparallel b-sheet structures (C-O stretch (76%), C-N stretch (14%), CCN deformation (10%))
+ve 2850 C-H symmetric stretch of -CH2 in fatty acids, lipids and proteins
+ve 2955 C-H antisymmetric stretch of -CH3 in fatty acids, lipids and proteins
ve 1532 Amide II of b-sheets (NH bend (43%), C-N stretch (29%), CO bend (15%), C-C stretch (9%), N-C stretch (8%))
ve 1577 Amide II (NH bend (43%), C-N stretch (29%), CO bend (15%), C-C stretch (9%), N-C stretch (8%))
ve 1621 Amide I of aggregated strand structures (C-O stretch (76%), C-N stretch (14%), CCN deformation (10%))
ve 1664 Amide I of turns 310 helical structure (C-O stretch (76%), C-N stretch (14%), CCN deformation (10%))
ve 1672 Amide I of turns structure (C-O stretch (76%), C-N stretch (14%), CCN deformation (10%))
ve 2920 C-H stretch (asymmetric) of 4CH2 in fatty acids, lipids, proteins
Spectral assignments taken from references Meurens et al (1996); Tamm and Tatulain (1997); Dovbeshko et al (2000); Naumann (2001); Cai and Ram Singh (2004); and Meade
et al (2007).
Table 3 Sensitivities and specificities observed for T1 and T2 and T3 and
T4 at 95 and 90% confidence limits and overall sensitivities and specificities
for (A) vector normalised, (B) vector normalised with first derivative and
(C) vector normalised with second derivative
Clinical stage T1 and T2 T3 and T4 Overall
(A)
Confidence limit 95% 90% 95% 90% 95% 90%
Sensitivity (%) 94.9 92.3 87.5 84.4 91.2 88.4
Specificity (%) 91 91 94.9 97.4 93.0 94.2
(B)
Confidence limit 95% 90% 95% 90% 95% 90%
Sensitivity (%) 92.3 89.7 84.4 78.1 88.4 83.9
Specificity (%) 87.5 90.6 97.4 97.4 92.5 94.0
(C)
Confidence limit 95% 90% 95% 90% 95% 90%
Sensitivity (%) 92.3 89.7 84.4 81.3 88.4 85.5
Specificity (%) 84.4 84.4 92.3 92.3 88.4 88.4
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constituents of local area of tissue within a biopsy (Diem et al,
2004).
To reduce the variability in Gleason grades between specimens,
we graded our specimens using a single histopathologist to assign
Gleason scores to CaP tissue sections. Latouf and Saad (2002)
reported that there was only 29.2% agreement in the assignment of
Gleason score to biopsy and radical prostatectomy samples when
assessment was made by multiple pathologists. However, the same
study showed that when samples were assessed by a single
pathologist, the agreement rose to 48.7%. They concluded that
assessment by the same pathologist reduces the discrepancy in the
Gleason grading of prostate biopsy.
Although Gleason grading is a useful clinical method, there are
clear difficulties with inter-observer variation. Additional diag-
nostic modalities may provide an important adjunct to diagnosis
and, in particular, to the specific identification of tumours with
aggressive biopotential. We have shown in earlier studies (Gazi
et al, 2006) that chemometric analysis using vibrational spectro-
scopy is a viable tool for assessing paraffin-embedded formalin-
fixed CaP biopsies. This study has developed the technique still
further, resulting in a significant improvement in the overall
sensitivity and specificity. This was 73 and 86.3% in the earlier
work (Gazi et al, 2006) as compared with 92.3 and 98.9% achieved
in this study.
One of the limitations with this study and the study by Gazi et al
(2006) is that the Gleason grading system was used as the reference
standard for the development of the diagnostic algorithms. This
methodology is inevitably flawed, as it will tend to incorporate
problems inherent in the Gleason system into the new system.
However, it was felt to be important to investigate this novel area
in this manner to establish proof of principle. This goal has now
been achieved, with the data currently presented showing clearly
that FTIR-based methods can identify and discriminate between
CaPs of different types. A study utilising archival tissue from
several different tissue banks, increasing the number of cases,
would provide a greater test for the discrimination. Future study
will now concentrate upon the development of a spectral grading
scale in anticipation that this approach may yield alternative and
potentially complementary methods for the assessment of CaP.
One of the promising features of these results was the ability to
identify a difference in the tissue characteristics of locally confined
and locally invasive tumours. The spectral differences between the
Gleason scores (Table 2 and Figure 3) occur in the amide I (1600–
1700 cm1), amide II (1510–1580 cm1) and amide III (1200–
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Figure 4 (A) Discriminant function plot showing separation based on model A (vector-normalised model) upon the training set (red digits) and test set
(blue digits) with 95% (blue ellipse) and 90% (green ellipse) confidence limits, where 1¼T1 and T2 and 2¼T3 and T4, and (B) loading plots for
discriminant function 1. DFA – DF1 vs DF2.
Table 4 Major spectral peaks responsible for the 2-band discrimination and proposed biomolecular assignments for discriminant function 1
Direction Wavenumber (cm1) Proposed biomolecular assignment
+ve 1068 C-O stretch, deoxyribose/ribose, DNA, RNA
+ve 1265 Amide III (NH bend (55%), C-C stretch (19%), C-N stretch (15%), CO bend (11%)) or PO2
 stretch, RNA, DNA
+ve 1415 C-N stretch, N-H, C-H deformation
+ve 1541 Amide II of a-helical structures (NH bend (43%), C-N stretch (29%), CO bend (15%), C-C stretch (9%), N-C stretch (8%))
+ve 1641 Amide I (C-O stretch (76%), C-N stretch (14%), CCN deformation (10%))
+ve 1645 Amide I (C-O stretch (76%), C-N stretch (14%), CCN deformation (10%))
+ve 1672 Amide I of turns structure (C-O stretch (76%), C-N stretch (14%), CCN deformation (10%))
+ve 2910 C-H stretch (asymmetric) of 4CH2 in fatty acids, lipids, proteins
ve 1244 Amide III (NH bend (55%), C-C stretch (19%), C-N stretch (15%), CO bend (11%))
ve 1290 Amide III (NH bend (55%), C-C stretch (19%), C-N stretch (15%), CO bend (11%))
ve 1364 Amide III (NH bend (55%), C-C stretch (19%), C-N stretch (15%), CO bend (11%))
ve 1558 Amide II (NH bend (43%), C-N stretch (29%), CO bend (15%), C-C stretch (9%), N-C stretch (8%))
ve 1655 Amide I of a-helical (C-O stretch (76%), C-N stretch (14%), CCN deformation (10%))
ve 1683 Amide I of turns or antiparallel b-sheet structures (C-O stretch (76%), C-N stretch (14%), CCN deformation (10%))
ve 1718 C-O stretch of carbonic acid
ve 2850 C-H symmetric stretch of –CH2 in fatty acids, lipids and proteins
ve 2918 C-H stretch (asymmetric) of 4CH2 in fatty acids, lipids and proteins
ve 2955 C-H antisymmetric stretch of –CH3 in fatty acids, lipids and proteins
Spectral assignments taken from references Meurens et al (1996); Tamm and Tatulain (1997); Dovbeshko et al (2000); Naumann (2001); Cai and Ram Singh (2004); and Meade
et al (2007).
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1400 cm1) regions of the spectra. This suggests a difference in the
protein content of the cancerous tissue as the cancer progresses to
more aggressive states. Meurens et al (1996) show the amide I and
amide II bands to be among the most significant in relation to
breast carcinoma, Fabian et al (2006) utilise the amide II region to
differentiate colorectal adenocarcinoma from non-cancerous tissue
and Bamberry et al (2004) reported that the major spectral
differences between the different cells in cervical cancer tissue
predictably occur in the amide I region. The majority of the study
in FTIR has focussed upon the ability to discriminate cancerous
from non-cancerous tissue. Ductal carcinoma in situ has been
differentiated from benign breast tissue, with 93% classified
correctly (Fabian et al, 2006). Colorectal adenocarcinoma tissue
(Lasch et al, 2002) has been investigated in this way with an overall
classification accuracy of 95%. Both these studies used optimised
artificial neural networks to process the spectral data. This study
has developed spectroscopic analysis further by utilising a PC-DFA
algorithm to identify the difference in tumour grade and to predict
the absence of local invasion in CaP biopsies. The prediction of
biopotential is of particular importance in CaP, where there is a
pressing need to differentiate between the indolent and aggressive
forms of the disease. The former represents the majority of cancers
diagnosed through screening, whereas the latter is responsible
for a large number of male cancer deaths (Albertsen et al, 2005;
Parker et al, 2006). The results presented herein suggest that the
differing biopotential of cancer may be determined by different
protein structures corresponding to changes in the amide I peak in
the FTIR spectra. The proposed spectral assignments for the
positive direction of discriminant function 1 (the spectral peaks
GSo7 and GS47 from GS¼ 7) have two spectral loading peaks
that can be related to a-helical structures, whereas the peaks in the
negative direction (the spectral peaks that discriminate GS¼ 7
from GSo7 and GS47) have amide I spectral peaks that can be
related to a-helical structure and antiparallel b-sheets/aggregated
strands.
The lipid region also aids the differentiation within discriminant
function 1, with spectral loading peaks for both groups illuminat-
ing different peaks in the lipid region (Figure 3, Table 2).
Differentiation based on lipid characteristics has already been
proven useful in breast cancer in the differentiation of benign from
malignant breast disease (Fabian et al, 2006). Discriminant
function 2 is discriminating GSo7 and GS47. The GS¼ 7
centroid lies close to the zero point on the discriminant function
2 axis, showing that GS¼ 7 has components that are present in
both GSo7 and GS47. As the GS¼ 7 group is made from Gleason
grades 3 and 4, the interrogation of only one of these grades in the
CaP tissue will provide it with attributes of the GSo7 or GS47
group. Using this discrimination to shed light upon the
biochemicals responsible, we can stipulate that the GSo7 group
uses spectral peaks that can be attributed to DNA/RNA and a-
helical, unordered turns or antiparallel b-sheet protein structures
and the GS47 group uses b-sheet, aggregated strand, 310 helical
and turns protein structures. The major peaks in the loadings that
could be used as a biomarker to distinguish aggressiveness of
cancer occur in discriminant function 2. Peaks at 1653 and
1683 cm1, which are attributable to amide I peaks (Table 2B),
are prominent in the loadings for GSo7 and peaks 2920 and
1577 cm1, attributable to amide II and C-H stretch asymmetric
(Table 2B), are prominent in the loadings for GS47.
Correlation of FTIR PC-DFA spectral signature with
clinical stage
To our knowledge, this is the first time that FTIR spectroscopy has
been shown to correlate with the local biopotential of CaP. The
importance of the identification of tumour aggression has already
been documented, but the data from this study also suggest that it
may be possible to facilitate the identification of those patients with
T3 and T4 disease from those with disease that is truly localised to
the prostate. This is a potentially important finding that may be of
particular utility in treatment planning, where pathological upsta-
ging of disease previously thought to be of lower stage is a common
problem. The FTIR PC-DFA discrimination shows that there is a
valid biochemical difference between the two groups of T stages.
This may be useful not only for interrogation of CaP tissue, but also
in the field of biochemical marker development.
The spectral loading peaks responsible for this important
discrimination between the two-band T stage criteria (Table 3
and Figure 4) again are based in the amide and lipid regions, with
T1 and T2 using DNA/RNA and a-helical structures and T3 and T4
using C-O and C-C stretches, C-O-H and C-O-C deformations of
carbohydrates and aggregated strands, and a-helical and antipar-
allel b-sheet protein structures. The major peaks in the loadings
that could be used as a biomarker to indicate local aggressiveness
are at 1558 cm1, attributable to amide II (for less aggressive
locally) (Table 4), and 1541 cm1, attributable to amide II of
a-helical structures (more aggressive locally) (Table 4). As with
biochemical grading of CaP biopsies by FTIR, FTIR prediction of
biopotential relies on detecting subtle changes in protein
conformations relating to individual tumour behaviour.
In conclusion, this study reports the use of FTIR combined with
PC-DFA to attain overall sensitivities and specificities of 92.3 and
98.9%, respectively, to predict Gleason scores o7, ¼ 7 and 47.
These results represent a significant increase in accuracy when
compared with the earlier reports. The results also show for the
first time that a two-band criterion-based system identifies
characteristics that differentiate between tumours that are
clinically confined to the prostate from those that are clinically
invasive. These findings have significant potential importance in
the development of better techniques for the diagnosis, prognos-
tication and treatment planning in CaP.
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